Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

Brazeau, Paul; Vale, Wylie; Burgus, Roger; Ling, Nicholas; Butcher, Madalyn; Rivier, Jean; Guillemin, Roger

doi:10.1126/science.179.4068.77

Cited by 3,417 publications

(1,303 citation statements)

References 9 publications

Supporting

Mentioning

1,248

Contrasting

Unclassified

Order By: Relevance

“…Although the suppression of somatotropin secretion by the administration of a long-acting analogue of somatostatin [94] has been considered as a possible adjunct to insulin treatment [88], reports of somatostatin's numerous other inhibitory effects [95,96] and the obvious drawback of suppressing a growth-promoting substance in young patients has diminished the prospect of its therapeutic use. In the more distant future one could visualize the development of agents which could interfere with some of the postribosomal steps of basement membrane assembly such as hydroxylation, glycosylation, export and cross-link formation.…”

Section: Therapeutic Considerationsmentioning

confidence: 99%

Search for a biochemical basis of diabetic microangiopathy

1976

Diabetologia

191

View full text Add to dashboard Cite

Summary. Diabetic microangiopathy, particularly as seen in the renal glomerulus, is characterized by morphological and biochemical alterations of the capillary basement membrane. Observations from a number of disciplines have indicated that the microvascular disease is not a separately inherited entity but a true consequence or "complication" of insulin deficiency. An evaluation of the biochemical events which could be responsible for the basement membrane lesions of diabetes indicates that the hyperglycemia or plasma somatotropin elevation of this disease alone, or in combination, may play an important role.

show abstract

Section: Therapeutic Considerationsmentioning

confidence: 99%

Search for a biochemical basis of diabetic microangiopathy

1976

Diabetologia

191

View full text Add to dashboard Cite

show abstract

“…Recently, a growth hormone (GH) release inhibiting factor, somatostatin, was isolated from sheep hypothalamus [1]. The same authors demonstrated that, in man, somatostatin, besides inhibiting GH release, lowered basal plasma insulin levels [2].…”

Section: Introductionmentioning

confidence: 99%

Effect of somatostatin on glucose induced insulin release in isolated perfused rat pancreas and isolated rat pancreatic islets

1974

View full text Add to dashboard Cite

“…SRIF is a tetradecapeptide that was first identified in the hypothalamus [17]. Two forms of SRIF have been recognized, SRIF-14, the form identified originally, and SRIF-28, a congener of SRIF-14 extended at the N terminus that was discovered subsequently [18].…”

Section: Neuropeptides As Anti-ischemic Agentsmentioning

confidence: 99%

The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story

Cervia¹,

Casini²

2013

Current Neuropharmacology

View full text Add to dashboard Cite

The multiplicity of peptidergic receptors and of the transduction pathways they activate offers the possibility of important advances in the development of specific drugs for clinical treatment of central nervous system disorders. Among them, retinal ischemia is a common clinical entity and, due to relatively ineffective treatment, remains a common cause of visual impairment and blindness. Ischemia is a primary cause of neuronal death, and it can be considered as a sort of final common pathway in retinal diseases leading to irreversible morphological damage and vision loss. Neuropeptides and their receptors are widely expressed in mammalian retinas, where they exert multifaceted functions both during development and in the mature animal. In particular, in recent years somatostatin and pituitary adenylate cyclase activating peptide have been reported to be highly protective against retinal cell death caused by ischemia, while data on opioid peptides, angiotensin II, and other peptides have also been published. This review provides a rationale for harnessing the peptidergic receptors as a potential target against retinal neuronal damages which occur during ischemic retinopathies.

show abstract

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

Cited by 3,417 publications

References 9 publications

Search for a biochemical basis of diabetic microangiopathy

Search for a biochemical basis of diabetic microangiopathy

Effect of somatostatin on glucose induced insulin release in isolated perfused rat pancreas and isolated rat pancreatic islets

The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story

Contact Info

Product

Resources

About